- Home
- TVTX vs HOMB Comparison
TVTX vs HOMB Comparison
Compare TVTX & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVTX | HOMB |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.2B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | TVTX | HOMB |
|---|---|---|
| Price | $62.14 | $31.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $40.62 | $31.50 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-04-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 92.89 | 19.90 |
| EPS | N/A | ★ 1.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $44.76 | $10.99 |
| Revenue Next Year | $35.51 | $5.14 |
| P/E Ratio | ★ N/A | $26.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $25.50 |
| 52 Week High | $66.24 | $31.70 |
Technical Indicators
Market Signals| Indicator | TVTX | HOMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 67.00 |
| Support Level | $53.76 | $30.51 |
| Resistance Level | $66.24 | $31.70 |
| Average True Range (ATR) | 2.59 | 0.45 |
| MACD | 0.27 | -0.08 |
| Stochastic Oscillator | 67.32 | 81.51 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.